26,035 Shares in Immunome, Inc. $IMNM Acquired by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 26,035 shares of the company’s stock, valued at approximately $552,000.

Several other large investors have also recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. lifted its position in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after buying an additional 5,003,824 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Immunome during the 2nd quarter valued at $186,588,000. Vanguard Group Inc. increased its stake in shares of Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after acquiring an additional 1,144,788 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Immunome by 10.1% in the second quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock worth $110,404,000 after acquiring an additional 478,239 shares during the last quarter. Finally, Primecap Management Co. CA raised its holdings in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after acquiring an additional 1,667,432 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insiders Place Their Bets

In other Immunome news, CFO Max Rosett sold 60,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the sale, the chief financial officer owned 54,037 shares of the company’s stock, valued at $985,094.51. This trade represents a 52.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the completion of the sale, the insider directly owned 50,366 shares in the company, valued at $1,263,682.94. This trade represents a 64.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 682,310 shares of company stock valued at $15,675,566. Company insiders own 7.21% of the company’s stock.

Wall Street Analysts Forecast Growth

IMNM has been the subject of a number of research reports. Leerink Partners reduced their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Truist Financial raised their price target on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. HC Wainwright reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Barclays began coverage on Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective on the stock. Finally, Wedbush lifted their target price on shares of Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Immunome Trading Up 1.0%

NASDAQ IMNM opened at $27.33 on Thursday. Immunome, Inc. has a 1 year low of $8.66 and a 1 year high of $30.06. The company has a fifty day simple moving average of $24.67 and a 200 day simple moving average of $22.51. The company has a market cap of $3.10 billion, a P/E ratio of -10.80 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Equities research analysts forecast that Immunome, Inc. will post -2.38 EPS for the current fiscal year.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.